Home > Healthcare > Biotechnology > Bioservices > Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market Share

Report ID: GMI5689
Published Date: May 2023
Report Format: PDF

Download Free Sample

Cell & Gene Therapy Manufacturing Services Market Share

Some of the major market players operating in the cell & gene therapy manufacturing services market are:

Merck KGaA
F. Hoffmann-La Roche Ltd
Boehringer Ingelheim
Cellular Therapeutics
Hitachi Chemical Co Ltd
Bluebird Bio Inc
Takara Bio Inc
Miltenyi Biotec,
Thermo Fisher Scientific, Inc
Samsung Biologics,

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of cell and gene therapy manufacturing services crossed USD 4.8 billion in 2022 and could register over 19.9% CAGR between 2023 and 2032, owing to regulatory support, enhanced manufacturing technology and a surge in investments worldwide.

The cell segment holds the major share of cell and gene therapy manufacturing services industry, with increasing number of clinical trials and the need to provide advanced therapeutic products to a growing consumer base.

The oncology applications is expected to grow at over 20% CAGR during 2023-2032, due to factors such as need for personalized medicine and advancements in genetic engineering.

North America held over 46% share of cell and gene therapy manufacturing services market in 2022 and is growing at a steady pace, with the presence of a large number of CROs, increased spending on R&D and strong regulatory framework.